ImmunityBio Reports Strong Q1 Revenue Growth Despite EPS Miss
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 1 hour ago
0mins
Should l Buy IBRX?
Source: seekingalpha
- Earnings Highlights: ImmunityBio reported a Q1 GAAP EPS of -$0.62, missing expectations by $0.55, indicating ongoing challenges in profitability despite strong revenue growth.
- Revenue Surge: The company achieved Q1 revenue of $44.2 million, representing an approximately 168% year-over-year increase, exceeding market expectations by $0.26 million, showcasing robust sales momentum.
- Quarter-over-Quarter Analysis: Compared to Q4 2025, ImmunityBio's revenue grew by 15%, demonstrating the company's competitive position and sustained demand for its products in the market.
- Market Reaction: Despite the strong revenue performance, ImmunityBio's shares fell by 7% following the earnings report, reflecting investor concerns over profitability that may impact future investment decisions.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy IBRX?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on IBRX
Wall Street analysts forecast IBRX stock price to fall
3 Analyst Rating
3 Buy
0 Hold
0 Sell
Strong Buy
Current: 7.580
Low
5.00
Averages
7.33
High
9.00
Current: 7.580
Low
5.00
Averages
7.33
High
9.00
About IBRX
Immunitybio, Inc. is a vertically integrated, clinical-stage biotechnology company developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Using its applied science and platforms to treat cancers, including the development of potential cancer vaccines, as well as developing immunotherapies and cell therapies to reduce or eliminate the need for standard high-dose chemotherapy. Its platforms and their associated product candidates are designed to attack cancer and infectious pathogens by activating both the innate immune system, including NK cells, dendritic cells, and macrophages, as well as the adaptive immune system comprising B and T cells, in an orchestrated manner. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins, vaccine vectors, and cell therapies. Its biologic commercial product candidate, Anktiva, is an IL-15 superagonist antibody-cytokine fusion protein.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
ImmunityBio Reports 168% Revenue Growth in Q1 2026
- Significant Revenue Growth: ImmunityBio reported net product revenue of approximately $44.2 million in Q1 2026, reflecting a remarkable 168% year-over-year increase, which not only highlights strong demand for ANKTIVA but also indicates successful expansion into new markets.
- Strong Cash Position: As of March 31, 2026, the company had $380.9 million in cash, cash equivalents, and marketable securities, representing a 56.7% increase from $242.8 million as of December 31, 2025, providing ample funding for future R&D and market expansion initiatives.
- Clinical Trial Progress: The pivotal BCG-naïve NMIBC trial is fully enrolled, with the Independent Data Monitoring Committee confirming no additional patients are needed, laying the groundwork for a supplemental BLA submission in 2026 and demonstrating steady advancement in clinical development.
- Market Access Expansion: ANKTIVA has received approvals in approximately 34 countries, including its first approval in Asia by Macau, and achieved commercial availability within two months of announcing partnerships in the MENA region, showcasing the company's rapid global market positioning and strategic execution capabilities.
See More
ImmunityBio's Anktiva Application Decision Approaches
- FDA Review Deadline Approaches: The FDA's standard 60-day review window for ImmunityBio's resubmitted supplemental biologics license application for Anktiva expires Thursday, with potential approval significantly enhancing market competitiveness in treating difficult-to-treat non-muscle invasive bladder cancer.
- Positive Financial Outlook: Wall Street anticipates ImmunityBio's Q1 revenue to reach $43.9 million, a 15% increase from the previous quarter, while projected EBITDA losses are expected to narrow to $58 million, reflecting the company's ongoing growth momentum since Anktiva's commercial launch.
- Key Data Presentation: Next week at the American Urological Association Annual Meeting, ImmunityBio plans to present new comparative data on Anktiva against rival therapies, which could further boost investor confidence and elevate stock prices.
- FDA Leadership Turmoil: Recent leadership changes within the FDA's biologics and cancer divisions have raised concerns, potentially impacting the approval process for Anktiva, while market expectations for a more flexible stance on accelerated approvals are increasing.
See More
ImmunityBio Reports Strong Q1 Revenue Growth Despite EPS Miss
- Earnings Highlights: ImmunityBio reported a Q1 GAAP EPS of -$0.62, missing expectations by $0.55, indicating ongoing challenges in profitability despite strong revenue growth.
- Revenue Surge: The company achieved Q1 revenue of $44.2 million, representing an approximately 168% year-over-year increase, exceeding market expectations by $0.26 million, showcasing robust sales momentum.
- Quarter-over-Quarter Analysis: Compared to Q4 2025, ImmunityBio's revenue grew by 15%, demonstrating the company's competitive position and sustained demand for its products in the market.
- Market Reaction: Despite the strong revenue performance, ImmunityBio's shares fell by 7% following the earnings report, reflecting investor concerns over profitability that may impact future investment decisions.
See More
ImmunityBio Securities Class Action Reminder
- Filing Deadline: ClaimsFiler reminds investors that those who purchased ImmunityBio shares between January 19 and March 24, 2026, must file lead plaintiff applications by May 26, 2026, to participate in the securities class action lawsuit, ensuring their rights are protected.
- FDA Warning Letter: On March 24, 2026, CEO Richard Adcock received a warning letter from the FDA indicating that misleading advertisements for Anktiva violated the Federal Food, Drug, and Cosmetic Act, raising public health concerns due to the potential misrepresentation of the drug's efficacy.
- Stock Price Plunge: Following the FDA warning, ImmunityBio's stock price fell by 21% on March 24, 2026, losing $1.98 per share and closing at $7.42, reflecting market concerns over the company's compliance and future outlook.
- Legal Consultation Services: ClaimsFiler offers a free shareholder information service, allowing investors to access details on securities class actions and connect with Kahn Swick & Foti, LLC for legal options to safeguard their interests.
See More
ImmunityBio Faces Class Action Lawsuit
- Class Action Filed: Bragar Eagel & Squire has initiated a class action lawsuit against ImmunityBio in the Central District of California on behalf of investors who purchased securities between January 19, 2026, and March 24, 2026, highlighting serious concerns over the company's financial transparency.
- False Statements Allegation: The lawsuit alleges that ImmunityBio's executive Patrick Soon-Shiong materially overstated Anktiva's capabilities, which significantly undermined investor confidence in the company's business and prospects, potentially leading to a decline in stock price.
- Investor Losses: As the true details emerged, investors faced losses, with the lawsuit seeking damages and a deadline of May 26, 2026, for investors to apply as lead plaintiffs, indicating the urgency of the legal proceedings.
- Legal Consultation Offered: Bragar Eagel & Squire is offering no-cost legal consultations, encouraging affected investors to reach out, demonstrating the firm's commitment to protecting investor rights and providing support.
See More
ImmunityBio Faces Securities Class Action Lawsuit Over Misleading Claims
- Lawsuit Background: ImmunityBio is facing a securities class action lawsuit due to misleading claims made by its Chief Scientific Officer regarding Anktiva's efficacy, involving investors who purchased shares between January 19 and March 24, 2026, highlighting potential legal repercussions for the company's promotional practices.
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, stating that its promotional materials regarding Anktiva were misleading, particularly the claim that it could cure all cancers, resulting in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization.
- Investor Losses: Hagens Berman is investigating whether ImmunityBio intentionally misled investors, urging those who suffered significant losses to submit claims, indicating that the legal action could have profound implications for the company's future financial health.
- Public Health Impact: The FDA emphasized that ImmunityBio's misleading claims not only undermine investor confidence but also pose a public health risk, as these false statements could lead patients to have incorrect expectations about Anktiva's effectiveness.
See More
ImmunityBio Reports 168% Revenue Growth in Q1 2026
- Significant Revenue Growth: ImmunityBio reported net product revenue of approximately $44.2 million in Q1 2026, reflecting a remarkable 168% year-over-year increase, which not only highlights strong demand for ANKTIVA but also indicates successful expansion into new markets.
- Strong Cash Position: As of March 31, 2026, the company had $380.9 million in cash, cash equivalents, and marketable securities, representing a 56.7% increase from $242.8 million as of December 31, 2025, providing ample funding for future R&D and market expansion initiatives.
- Clinical Trial Progress: The pivotal BCG-naïve NMIBC trial is fully enrolled, with the Independent Data Monitoring Committee confirming no additional patients are needed, laying the groundwork for a supplemental BLA submission in 2026 and demonstrating steady advancement in clinical development.
- Market Access Expansion: ANKTIVA has received approvals in approximately 34 countries, including its first approval in Asia by Macau, and achieved commercial availability within two months of announcing partnerships in the MENA region, showcasing the company's rapid global market positioning and strategic execution capabilities.
See More
ImmunityBio's Anktiva Application Decision Approaches
- FDA Review Deadline Approaches: The FDA's standard 60-day review window for ImmunityBio's resubmitted supplemental biologics license application for Anktiva expires Thursday, with potential approval significantly enhancing market competitiveness in treating difficult-to-treat non-muscle invasive bladder cancer.
- Positive Financial Outlook: Wall Street anticipates ImmunityBio's Q1 revenue to reach $43.9 million, a 15% increase from the previous quarter, while projected EBITDA losses are expected to narrow to $58 million, reflecting the company's ongoing growth momentum since Anktiva's commercial launch.
- Key Data Presentation: Next week at the American Urological Association Annual Meeting, ImmunityBio plans to present new comparative data on Anktiva against rival therapies, which could further boost investor confidence and elevate stock prices.
- FDA Leadership Turmoil: Recent leadership changes within the FDA's biologics and cancer divisions have raised concerns, potentially impacting the approval process for Anktiva, while market expectations for a more flexible stance on accelerated approvals are increasing.
See More
ImmunityBio Reports Strong Q1 Revenue Growth Despite EPS Miss
- Earnings Highlights: ImmunityBio reported a Q1 GAAP EPS of -$0.62, missing expectations by $0.55, indicating ongoing challenges in profitability despite strong revenue growth.
- Revenue Surge: The company achieved Q1 revenue of $44.2 million, representing an approximately 168% year-over-year increase, exceeding market expectations by $0.26 million, showcasing robust sales momentum.
- Quarter-over-Quarter Analysis: Compared to Q4 2025, ImmunityBio's revenue grew by 15%, demonstrating the company's competitive position and sustained demand for its products in the market.
- Market Reaction: Despite the strong revenue performance, ImmunityBio's shares fell by 7% following the earnings report, reflecting investor concerns over profitability that may impact future investment decisions.
See More
ImmunityBio Securities Class Action Reminder
- Filing Deadline: ClaimsFiler reminds investors that those who purchased ImmunityBio shares between January 19 and March 24, 2026, must file lead plaintiff applications by May 26, 2026, to participate in the securities class action lawsuit, ensuring their rights are protected.
- FDA Warning Letter: On March 24, 2026, CEO Richard Adcock received a warning letter from the FDA indicating that misleading advertisements for Anktiva violated the Federal Food, Drug, and Cosmetic Act, raising public health concerns due to the potential misrepresentation of the drug's efficacy.
- Stock Price Plunge: Following the FDA warning, ImmunityBio's stock price fell by 21% on March 24, 2026, losing $1.98 per share and closing at $7.42, reflecting market concerns over the company's compliance and future outlook.
- Legal Consultation Services: ClaimsFiler offers a free shareholder information service, allowing investors to access details on securities class actions and connect with Kahn Swick & Foti, LLC for legal options to safeguard their interests.
See More
ImmunityBio Faces Class Action Lawsuit
- Class Action Filed: Bragar Eagel & Squire has initiated a class action lawsuit against ImmunityBio in the Central District of California on behalf of investors who purchased securities between January 19, 2026, and March 24, 2026, highlighting serious concerns over the company's financial transparency.
- False Statements Allegation: The lawsuit alleges that ImmunityBio's executive Patrick Soon-Shiong materially overstated Anktiva's capabilities, which significantly undermined investor confidence in the company's business and prospects, potentially leading to a decline in stock price.
- Investor Losses: As the true details emerged, investors faced losses, with the lawsuit seeking damages and a deadline of May 26, 2026, for investors to apply as lead plaintiffs, indicating the urgency of the legal proceedings.
- Legal Consultation Offered: Bragar Eagel & Squire is offering no-cost legal consultations, encouraging affected investors to reach out, demonstrating the firm's commitment to protecting investor rights and providing support.
See More
ImmunityBio Faces Securities Class Action Lawsuit Over Misleading Claims
- Lawsuit Background: ImmunityBio is facing a securities class action lawsuit due to misleading claims made by its Chief Scientific Officer regarding Anktiva's efficacy, involving investors who purchased shares between January 19 and March 24, 2026, highlighting potential legal repercussions for the company's promotional practices.
- FDA Warning Letter: The FDA issued a warning letter to ImmunityBio, stating that its promotional materials regarding Anktiva were misleading, particularly the claim that it could cure all cancers, resulting in a more than 21% drop in share price on March 24, 2026, erasing nearly $2 billion in market capitalization.
- Investor Losses: Hagens Berman is investigating whether ImmunityBio intentionally misled investors, urging those who suffered significant losses to submit claims, indicating that the legal action could have profound implications for the company's future financial health.
- Public Health Impact: The FDA emphasized that ImmunityBio's misleading claims not only undermine investor confidence but also pose a public health risk, as these false statements could lead patients to have incorrect expectations about Anktiva's effectiveness.
See More
